Table 4. The changes of lipid profile and blood pressure after acarbose or metformin treatment in normal weight, overweight and obese patients with newly diagnosed type 2 diabetes.
| Parameters | BMI<24 | BMI 24–28 | BMI>28 | |||
| Acabose (n = 106) | Metfomin (n = 110) | Acabose (n = 212) | Metfomin (n = 193) | Acabose (n = 75) | Metfomin (n = 88) | |
| Systolic BP, mm Hg | ||||||
| 24 weeks | −0.03 (−2.26– 2.20) | −1.58 (−4.10– 0.93) | −2.50 (−4.23– −0.77) | −1.96 (−4.10– 0.19) | 0.54 (−3.02– 4.11) | −0.67 (−3.28– 1.93) |
| 48 weeks | 0.64 (−1.74– 3.02) | 0.45 (−1.90– 2.81) | −1.40 (−3.31– 0.50) | −2.00 (−4.03– 0.03) | 1.19 (−2.01– 4.39) | −1.47 (−4.33– 1.40) |
| Diastolic BP, mm Hg | ||||||
| 24 weeks | −1.37 (−3.00– 0.27) | −1.26 (−3.04– 0.52) | −2.45 (−3.77– −1.14) | −1.34 (−2.81– 0.14) | −1.73 (−4.35– 0.89) | −2.06 (−4.18– 0.06) |
| 48 weeks | −0.16 (−2.08– 1.75) | −1.10 (−2.68– 0.49) | −2.24 (−3.53– −0.96) | −1.29 (−2.73– 0.14) | −3.16 (−5.90– −0.42) | −2.68 (−4.93– −0.42) |
| TC, mmol/L | ||||||
| 24 weeks | −0.30 (−0.49– −0.11) | −0.26 (−0.46 − −0.06) | −0.42 (−0.57– −0.27) | −0.33 (−0.48 − −0.17) | −0.49 (−0.71– −0.26) | −0.51 (−0.73 − −0.29) |
| 48 weeks | −0.19 (−0.41– 0.02) | −0.22 (−0.41 − −0.03) | −0.39 (−0.54– −0.23) | −0.34 (−0.52 − −0.16) | −0.45 (−0.70– −0.20) | −0.46 (−0.71 − −0.22) |
| LDL-C, mmol/L | ||||||
| 24 weeks | −0.19 (−0.38– −0.01) | −0.17 (−0.33 − −0.02) | −0.15 (−0.27– −0.02) | −0.21 (−0.34 − −0.08) | −0.16 (−0.35– 0.03) | −0.35 (−0.52 − −0.19) |
| 48 weeks | −0.07 (−0.27– 0.13) | −0.09 (−0.23 − −0.06) | −0.09 (−0.21– 0.04) | −0.13 (−0.28 − 0.02) | 0.02 (−0.20– 0.24) | −0.20 (−0.39 − −0.01) |
| HDL-C, mmol/L | ||||||
| 24 weeks | 0.07 (0.00– 0.13) | 0.03 (−0.05– 0.11) | 0.00 (−0.03– 0.03) | −0.04 (−0.09– 0.00) | 0.07 (0.01– 0.13) | 0.03 (−0.02– 0.08) |
| 48 weeks | 0.06 (−0.01– 0.12) | 0.00 (−0.09– 0.08) | 0.01 (−0.03– 0.05) | −0.03 (−0.07– 0.02) | 0.01 (−0.04– 0.07) | −0.03 (−0.09– 0.03) |
| TG, mmol/L | ||||||
| 24 weeks | −0.32 (−0.87– 0.24) | 0.26 (−0.33– 0.86) | −0.47 (−0.85– −0.09) | 0.15 (−0.15– 0.45)* | −0.94 (−1.36– −0.52) | −0.13 (−0.48– 0.21)** |
| 48 weeks | −0.29 (−0.56– −0.02) | −2.13 (−3.09 − −1.18) | −0.48 (−0.74– −0.21) | 0.20 (−0.289– 0.70)* | −0.93 (−1.40– −0.45) | −0.17 (−0.67 − −0.32)* |
| Non-HDL-C, mmol/L | ||||||
| 24 weeks | −0.36 (−0.56– −0.17) | −0.27 (−0.46 − −0.07) | −0.42 (−0.58– −0.27) | −0.29 (−0.44 − −0.13) | −0.56 (−0.77– −0.34) | −0.54 (−0.76 − −0.33) |
| 48 weeks | −0.25 (−0.46– −0.05) | −0.21 (−0.39 − −0.03) | −0.40 (−0.55– −0.25) | −0.31 (−0.49 − −0.13) | −0.47 (−0.70– −0.23) | −0.44 (−0.69 − −0.19) |
| optimal LDL−C rate, % | ||||||
| 24 weeks | 43.5 | 34.4 | 30.5 | 40.2 | 28.6 | 43.9* |
| 48 weeks | 39.5 | 36.6 | 32.8 | 32.5 | 19.7 | 42.1** |
| optimal non-HDL-C rate, % | ||||||
| 24 weeks | 51.1 | 45.8 | 41.4 | 42.7 | 38.6 | 45.1 |
| 48 weeks | 44.2 | 44.1 | 42.1 | 40.8 | 45.5 | 42.1 |
Data are shown as difference (95% CI) vs baseline, unless optimal LDL-C rate and optimal non-HDL-C rate. BP: blood pressure; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; optimal LDL-C rate: the proportion of patients with optimal levels of LDL-C; optimal non-HDL-C rate: the proportion of patients with optimal levels of non-HDL-C. The optimal levels of LDL-C and non-HDL-C were defined as: LDL-C<100 mg/dL (2.6 mmol/L) and non-HDL-C<130 mg/dL (2.6 mmol/L) [7].
*significantly different at P<0.05 vs baseline;
**significantly different at P<0.01 vs baseline.